drugset / Trial / NCT06162065

Effectiveness of Oral Boldo in Women With Overactive Bladder

NCT06162065

RandomizedParallel-groupSingle-blindTreatment

Summary

The objective of this clinical trial is to know if boldo oral powder capsules works well in the management of urinary symptoms in women with overactive bladder. The main questions it aims to answer are: * Is boldo supplementation safe? * Does boldo improve urinary parameters and body stability? 5 participants will be treated with an oral antimuscarinic (oxybutynin) and supplemented with oral spray bolus. The urinary chart will be applied to measure urinary frequency and voiding intervals. In addition, urinary symptoms and the level of discomfort they generate will be measured. Finally, the MiniBest test will be applied using a portable device which acts as an inertial sensor to record the movements made. For comparative purposes, 5 women who will only be treated with the oral antimuscarinic (oxybutynin) will be measured to see if there are significant differences between the medication alone versus the supplemented medication.

Timeline

Start
2023-11-01
Primary completion
2024-01-31
Completion
2024-03-30

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject boldo Unknown 340 mg Oral
Subject boldo Unknown 380 mg Oral
Background Oxybutynin Small molecule 10 mg Oral

Indications